{"id":"W145182321","doi":"10.1177/1756285608098359","title":"Review: Escalating immunotherapy of multiple sclerosis","year":2008,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Natalizumab; Glatiramer acetate; Alemtuzumab; Multiple sclerosis; Mitoxantrone; Immunotherapy; Clinical trial; Disease; Intensive care medicine; Fingolimod; Oncology; Immunosuppression; Immunology; Internal medicine; Transplantation; Chemotherapy; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001590322,0.001243449,0.00287433,0.002374278,0.0003427333,0.001533407,0.001521611,0.001971192,0.006886983],"category_scores_gemma":[0.004078671,0.000278405,0.0008677556,0.003612505,0.0006303375,0.001736726,0.0005313121,0.001572464,0.002474236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001133863,"about_ca_system_score_gemma":0.001499962,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001329439,"about_ca_topic_score_gemma":0.002332859,"domain_scores_codex":[0.9988528,0.0004164991,0.0002412522,0.0001073082,0.0003434868,0.00003851537],"domain_scores_gemma":[0.9982811,0.001014629,0.0002884264,0.00003385517,0.0002954947,0.00008648865],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004582516,0.00008156672,0.000203857,0.1140427,0.000638461,0.0003501956,0.00006610397,0.0003606163,0.0007129809,0.001202054,0.130253,0.7516302],"study_design_scores_gemma":[0.0003890713,0.0003863949,0.002159613,0.05365296,0.001428317,0.002610088,0.0001208425,0.0001336524,0.0004191344,0.001973945,0.9366904,0.00003557799],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001042276,0.9969968,0.00009759401,0.000629786,0.001171048,0.00004148766,0.0000280658,0.000007294165,0.0009237976],"genre_scores_gemma":[0.0007330935,0.996406,0.0002582238,0.001273956,0.0006951428,0.00003765034,0.00003944623,0.000002067117,0.0005543674],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006886983,"threshold_uncertainty_score":0.02303928,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08269379223139042,"score_gpt":0.3385518491725664,"score_spread":0.2558580569411759,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}